Aclaris Therapeutics (ACRS) Misses Q4 EPS by 1c

Aclaris Therapeutics (NASDAQ: ACRS) reported Q4 EPS of ($0.16), $0.01 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $1.3 million versus the consensus estimate of $1.94 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• Apollo Global Management (APO) call put ratio 1 call to 6.8 puts a focus on a spreader of 9K contracts January 95 and 135 puts
• Morgan Stanley Upgrades Sonova Holding AG (SOON:SW) (SONVY) to Equalweight
• Morgan Stanley Upgrades QIAGEN NV (QIA:GR) (QGEN) to Overweight